Homology and molecular dynamics models of toll-like receptor 7 protein and its dimerization

Chemical Biology and Drug Design

Volumn 83, Issue 6, 2014, Pages 656-665

  Tseng, Chih Yuan ^a   Gajewski, Melissa ^b   Danani, Andrea ^b   Tuszynski, Jack A ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF APPLIED SCIENCES AND ARTS OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

homology modeling; ligand docking; molecular dynamics; toll like receptors

Indexed keywords

IMIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; LIGAND;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; DIMERIZATION; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; CATALYTIC DOMAIN; DIMERIZATION; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; SEQUENCE HOMOLOGY; TOLL-LIKE RECEPTOR 7;

EID: 84901195911     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12278     Document Type: Article

References (48)

1. Janeway C.A. Jr, Medzhitov R., (2002) Innate immune recognition. Annu Rev Immunol; 20: 197-216.
2. Takeda K., Akira S., (2005) Toll-like receptors in innate immunity. Int Immunol; 17: 1-14.
3. Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr, (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature; 388: 394-397.
4. Review on Toll-Like Receptors (TLR) and TLR pathways-Invivogen. http://www.invivogen.com/review-tlr. Accessed 29 May 2013
5. Tanji H., Ohto U., Shibata T., Miyake K., Shimizu T., (2013) Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science; 339: 1426-1429.
6. Zähringer U., Lindner B., Inamura S., Heine H., Alexander C., (2008) TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology; 213: 205-224.
7. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., Bauer S., (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol; 3: 499.
8. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S., (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science; 303: 1526-1529.
9. Lauw F.N., Caffrey D.R., Golenbock D.T., (2005) Of mice and man: TLR11 (finally) finds profilin. Trends Immunol; 26: 509-511.
10. Hennessy E.J., Parker A.E., O'Neill L.A.J., (2010) Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov; 9: 293-307.
11. Nishiya T., DeFranco A.L., (2004) Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem; 279: 19008-19017.
12. Rakoff-Nahoum S., Medzhitov R., (2009) Toll-like receptors and cancer. Nat Rev Cancer; 9: 57-63.
13. Wang D., Precopio M., Lan T., Yu D., Tang J.X., Kandimalla E.R., Agrawal S., (2010) Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther; 9: 1788-1797.
14. Dummer R., Hauschild A., Becker J.C., Grob J.J., Schadendorf D., Tebbs V., Skalsky J., Kaehler K.C., Moosbauer S., Clark R., Meng T.C., Urosevic M., (2008) An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res; 14: 856-864.
15. Dudek A.Z., Yunis C., Harrison L.I., Kumar S., Hawkinson R., Cooley S., Vasilakos J.P., Gorski K.S., Miller J.S., (2007) First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res; 13: 7119-7125.
16. Harrison L.I., Astry C., Kumar S., Yunis C., (2007) Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol; 47: 962-969.
17. Krieg A.M., (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene; 27: 161-167.
18. Sun S., Rao N.L., Venable J., Thurmond R., Karlsson L., (2007) TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets; 6: 223-235.
19. Macfarlane D.E., (1950) Manzel L (1998) Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol Baltim Md; 160: 1122-1131.
20. Lipford G., Forsbach A., Zepp C., Nguyen T., Weeratna R., McCluskie M., Volimer J., Davis H., Krieg A.M., (2007) Selective Toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases.
21. First Safety Study in Humans of a Single Dose of CPG 52364-Full Text View-ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00547014. Accessed 30 May 2013.
22. Barrat F.J., Meeker T., Chan J.H., Guiducci C., Coffman R.L., (2007) Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol; 37: 3582-3586.
23. Wei T., Gong J., Rössle S.C., Jamitzky F., Heckl W.M., Stark R.W., (2011) A leucine-rich repeat assembly approach for homology modeling of the human TLR5-10 and mouse TLR11-13 ectodomains. J Mol Model; 17: 27-36.
24. Wei T., Gong J., Jamitzky F., Heckl W.M., Stark R.W., Rössle S.C., (2009) Homology modeling of human Toll-like receptors TLR7, 8, and 9 ligand-binding domains. Protein Sci; 18: 1684-1691.
25. Case D.A., Darden T.A., Cheatham T.E. III, Simmerling C.L., Wang J., Duke R.E., Luo R., et al,. (2012) AMBER 12.
26. Sali A., Blundell T.L., (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol; 234: 779-815.
27. Fiser A., Do R.K., Sali A., (2000) Modeling of loops in protein structures. Protein Sci; 9: 1753-1773.
28. Wallner B., Elofsson A., (2003) Can correct protein models be identified? Protein Sci; 12: 1073-1086.
29. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M., (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr; 26: 283-291.
30. McGuffin L.J., (2008) The ModFOLD server for the quality assessment of protein structural models. Bioinforma Oxf Engl; 24: 586-587.
31. Pawlowski M., Gajda M.J., Matlak R., Bujnicki J.M., (2008) MetaMQAP: a meta-server for the quality assessment of protein models. BMC Bioinformatics; 9: 403.
32. Torda A.E., Procter J.B., Huber T., (2004) Wurst: a protein threading server with a structural scoring function, sequence profiles and optimized substitution matrices. Nucleic Acids Res; 32: W532-W535.
33. Kelley L.A., Sternberg M.J.E., (2009) Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc; 4: 363-371.
34. Vallat B.K., Pillardy J., Májek P., Meller J., Blom T., Cao B., Elber R., (2009) Building and assessing atomic models of proteins from structural templates: learning and benchmarks. Proteins; 76: 930-945.
35. MaxCluster A tool for Protein Structure Comparison and Clustering. http://www.sbg.bio.ic.ac.uk/maxcluster/. Accessed 30 May 2013.
36. Guex N., Peitsch M.C., (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis; 18: 2714-2723.
37. Hess B., Kutzner C., van der Spoel D., Lindahl E., (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput; 4: 435-447.
38. Duan Y., Wu C., Chowdhury S., Lee M.C., Xiong G., Zhang W., Yang R., Cieplak P., Luo R., Lee T., Caldwell J., Wang J., Kollman P., (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem; 24: 1999-2012.
39. Jorgensen W.L., (1981) Quantum and statistical mechanical studies of liquids. 10. Transferable intermolecular potential functions for water, alcohols, and ethers. Application to liquid water. J Am Chem Soc; 103: 335-340.
40. Langevin P., (1905) Sur la téorie du mouvement Brownian. Ann Chim Phys; 5: 245.
41. Ryckaert J.-P., Ciccotti G., Berendsen H.J., (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys; 23: 327-341.
42. Hendlich M., Rippmann F., Barnickel G., (1997) LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J Mol Graph Model; 15 (359-363): 389.
43. Pocket-Finder: Pocket Detection. http://www.modelling.leeds.ac.uk/ pocketfinder/. Accessed 30 May 2013.
44. Forsbach A., Müller C., Montino C., Kritzler A., Nguyen T., Weeratna R., Jurk M., Vollmer J., (2012) Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands. J Interf Cytokine Res Off J Int Soc Interf Cytokine Res; 32: 254-268.
45. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J., (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem; 30: 2785-2791.
46. Tovchigrechko A., Vakser I.A., (2006) GRAMM-X public web server for protein-protein docking. Nucleic Acids Res; 34: W310-W314.
47. Comeau S.R., Gatchell D.W., Vajda S., Camacho C.J., (2004) ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res; 32: W96-W99.
48. Maschalidi S., Hässler S., Blanc F., Sepulveda F.E., Tohme M., Chignard M., van Endert P., Si-Tahar M., Descamps D., Manoury B., (2012) Asparagine endopeptidase controls anti-influenza virus immune responses through TLR7 activation. PLoS Pathog; 8: e1002841.